Urges FDA consideration of unique characteristics of cord blood
The unique characteristics of cord blood and related-tissue products and therapies should be acknowledged in the regulation of cellular products and regenerative medicine, according to testimony presented by the CBA at an FDA public hearing.
Quality products, market expansion, public education among key topics
The CBA Board of Directors has approved 32 policy statements on a wide spectrum of interests including quality and safety, research and development, legislation and regulation, market expansion and public education. The statements put association positions on the record and provide a framework for future policy development.
The CBA is an international, non-profit organization that promotes both public and family cord blood banking, with the objectives of saving lives, improving health and changing medicine.
Our priorities are advocacy, quality products and services, market expansion, research and development, and public and professional education. If you share these interests, you are cordially invited to join with us.
Expectant parents are faced with important decisions, even before their baby is born. One of the most important is a life-altering decision about whether to bank their baby’s umbilical cord blood, or donate it to help others. If the precious stem cells in cord blood are not banked, they are discarded as medical waste.
There’s no one choice that’s right for all parents. But health care professionals and parents have developed guidelines to help with the decision.